Trials / Completed
CompletedNCT02253004
Induction of Migraine Aura With Cilostazol
The Effect of the Selective PDE3 Inhibitor on Migraine With Aura Induction and Vascular Endothelial Function.
- Status
- Completed
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Herlev Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
In a double blind placebo-controlled cross-over study the effect of cilostazol on aura induction and endothelial response is tested in patient with migraine with aura.
Detailed description
Migraine with aura is associated to an increased risk of stroke. The mechanism behind such increased risk is not fully understood. Cilostazol induce headache and migraine in migraine patients and is used as secondary prevention of stroke. The effect on aura induction is not known. We investigate the aura inducing potential of cilostazol and associated changes in endothelial function.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cilostazol | Single oral administration of active or placebo one week apart |
| DRUG | Placebo |
Timeline
- Start date
- 2014-09-01
- Primary completion
- 2015-08-01
- Completion
- 2015-08-01
- First posted
- 2014-10-01
- Last updated
- 2015-08-21
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT02253004. Inclusion in this directory is not an endorsement.